Das chronische Koronarsyndrom beim älteren Patienten und Niereninsuffizienz – Was ist zu bedenken?

Zusammenfassung

Das chronische Koronarsyndrom (CCS) ist eine bedeutende kardiovaskuläre Erkrankung, die insbesondere ältere Patienten mit gleichzeitiger Niereninsuffizienz betrifft. Aufgrund des komplexen Zusammenspiels dieser Syndrome stellen Diagnose und Therapie stets eine besondere Herausforderung dar. Diese Arbeit adressiert aktuelle Erkenntnisse zur Pathophysiologie, Diagnostik und Behandlung und gibt einen Überblick über klinische Studien und evidenzbasierte Leitlinien.

Abstract

Chronic coronary syndrome (CCS) is a major cardiovascular disease that particularly affects older patients with concomitant renal insufficiency. Due to the complex interplay of these syndromes, diagnosis and therapy always pose a particular challenge. This paper addresses current findings on pathophysiology, diagnosis and treatment and provides an overview of clinical studies and evidence-based guidelines.

Was ist wichtig?

Das chronische Koronarsyndrom (CCS) betrifft insbesondere ältere Patienten mit chronischer Niereninsuffizienz (CKD) und stellt eine besondere Herausforderung dar.

Die Kombination beider Erkrankungen verschlechtert die Prognose erheblich, da sowohl diagnostische als auch therapeutische Maßnahmen durch altersbedingte physiologische Veränderungen und eine eingeschränkte Nierenfunktion limitiert sind.

Besonders problematisch sind die häufig unspezifische Symptomatik, die eingeschränkte Aussagekraft diagnostischer Verfahren und die erhöhte Komplikationsrate bei medikamentöser sowie interventioneller Therapie.

Ein individualisiertes, interdisziplinäres Management ist essenziell, um kardiovaskuläre Ereignisse zu reduzieren und die Lebensqualität der betroffenen Patienten zu verbessern.

Schlüsselwörter

chronisches Koronarsyndrom - älterer Patient - Niereninsuffizienz

Keywords

chronic coronary syndrome - renal insufficiency - elderly patient

Publikationsverlauf

Artikel online veröffentlicht:
02. April 2025

• Literatur

• 1 Vrints C, Andreotti F, Koskinas KC. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 45: 3415-3537
• 2 Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081
• 3 Sarnak MJ, Amann K, Bangalore S. et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74: 1823-1838
• 4 Konstantinidis I, Nadkarni GN, Yacoub R. et al. Representation of Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic Review. JAMA Intern Med 2016; 176: 121-124
• 5 Manjunath G, Tighiouart H, Ibrahim H. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55
• 6 Rittger H, Rieber J, Breithardt OA. et al. Influence of age on pain perception in acute myocardial ischemia: a possible cause for delayed treatment in elderly patients. Int J Cardiol 2011; 149: 63-67
• 7 Sosnov J, Lessard D, Goldberg RJ. et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006; 47: 378-384
• 8 Burton JO, Jefferies HJ, Selby NM. et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4: 1925-1931
• 9 Stefánsson BV, Brunelli SM, Cabrera C. et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol 2014; 9: 2124-2132
• 10 Szummer K, Lundman P, Jacobson SH. et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858
• 11 Faucon AL, Lambert O, Massy Z. et al. Sex and the Risk of Atheromatous and Nonatheromatous Cardiovascular Disease in CKD: Findings From the CKD-REIN Cohort Study. Am J Kidney Dis 2024; 84: 546-556.e1
• 12 SCORE2 working group, ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J and 2021; 42: 2439-2454
• 13 London GM, Guérin AP, Marchais SJ. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
• 14 Agarwal R, Pitt B, Rossing B. et al. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol 2023; 8: 732-741
• 15 Winther S, Svensson M, Jørgensen HS. et al. Diagnostic Performance of Coronary CT Angiography and Myocardial Perfusion Imaging in Kidney Transplantation Candidates. JACC Cardiovasc Imaging 2015; 8: 553-562
• 16 Wang LW, Fahim MA, Hayen A. et al. Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev 2011; (12) CD008691
• 17 Mc Murray, Scott D, Solomon MD. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
• 18 The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
• 19 Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 3: 259-305
• 20 Lee Y, Cho J, You S. et al. Moderate-intensity statin with ezetimibe vs. high intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J 2023; 14: 972-983
• 21 Mavrakanas TA, Chatzizisis YS, Gariani K. et al. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019; 14: 810-822
• 22 Shaw C, Nitsch D, Lee J. et al. Impact of an Early Invasive Strategy versus Conservative Strategy for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome in Patients with Chronic Kidney Disease: A Systematic Review. PLoS One 2016; 11
• 23 Shaw LJ, Berman DS, Maron DJ. et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291
• 24 Chung SC, Hlatky MA, Faxon D. et al. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol 2011; 58: 810-819
• 25 Herzog CA, Simegn MA, Xu Y. et al. Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. J Am Coll Cardiol 2021; 78: 348-361